Profund Advisors LLC Purchases 12,053 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Profund Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 340.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,589 shares of the biopharmaceutical company’s stock after purchasing an additional 12,053 shares during the quarter. Profund Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $6,199,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in ALNY. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $36,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $39,000. 92.97% of the stock is currently owned by institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,799 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the transaction, the chief executive officer owned 98,628 shares in the company, valued at $32,315,464.20. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the transaction, the executive vice president owned 23,406 shares of the company’s stock, valued at $7,483,834.44. This represents a 7.05% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 21,255 shares of company stock valued at $6,930,337. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ:ALNY opened at $286.27 on Tuesday. The stock has a fifty day simple moving average of $313.09 and a two-hundred day simple moving average of $363.40. The stock has a market capitalization of $38.22 billion, a price-to-earnings ratio of 78.22 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12-month low of $284.19 and a 12-month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business earned ($0.44) earnings per share. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on ALNY. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Royal Bank Of Canada lowered their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Finally, Needham & Company LLC lowered their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $471.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.